Global Health Data Exchange - Discover the World's Health Data

Seroprevalence of anti-SARS-CoV-2 IgG at the epidemic peak in French Guiana. Preprint

Nav

General Info
Geography 
France (FRA)
French Guiana
Coverage type 
Country
Time period covered 
07/2020 - 07/2020
Summary 

"The overall seroprevalence was 15.4% [9.3%-24.4%] among 480 participants, ranging from 4.0% to 25.5% across the different municipalities. The seroprevalence did not differ according to gender (p=0.19) or age (p=0.51). Among SARS-CoV-2 positive individuals, we found that 24.6% [11.5%-45.2%] reported symptoms consistent with COVID-19."

Citation
Authors 
Flamand C, Enfissi A, Bailly S, Sarmento CA, Beillard E, Gaillet M, Michaud C, Servas V, Clement N, Perilhou A, Carage T, Musso D, Carod J-F, Eustache S, Tourbillon C, Boizon E, James S, Djossou F, Salje H, Cauchemez S, Rousset D.
Journal 
medRxiv
Suggested citation 

Flamand C, Enfissi A, Bailly S, Sarmento CA, Beillard E, Gaillet M, Michaud C, Servas V, Clement N, Perilhou A, Carage T, Musso D, Carod J-F, Eustache S, Tourbillon C, Boizon E, James S, Djossou F, Salje H, Cauchemez S, Rousset D.

Seroprevalence of anti-SARS-CoV-2 IgG at the epidemic peak in French Guiana. Preprint. medRxiv. 2020.